The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer

Published:2019-04-09 Issue:1 Volume:15 Page:57-65
ISSN:1996-1812
Container-title:Cancer Urology
language:
Short-container-title:Onkourologiâ

Author:

Matveev V. B.¹^ORCID,Kirichek A. A.¹^ORCID,Safronova V. M.¹,Kokosadze N. V.¹,Khalmurzaev O. A.¹^ORCID,Kamolov B. Sh.¹^ORCID,Liubchenko L. N.¹^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Publisher

Publishing House ABV Press

Subject

Urology,Nephrology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference34 articles.

1. Zaridze D.G., Kaprin A.D., Stilidi I.S. Dynamics of morbidity and mortality from malignant tumors in Russia. Problemy onkologii = Problems in Oncology 2018;64(5):578—91. (In Russ.)].

2. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018:68(6):394—424. DOI: 10.3322/caac.21492. PMID: 30207593.

3. Alexeev B.Ya., Nyushko K.M., Kaprin A.D. Luteinizing hormone releasing hormone analogues in the treatment of pa¬tients with prostate cancer. Meditsinskiy Sovet = Medical Council 2018;19:96-100. (In Russ.). DOI: 10.21518/2079-701X-2018-19-96-100

4. Vale C.L., Burdett S., Rydzewska L.H. et al. Addition of docetaxel or bisphospho- nates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016;17(2):243—56. DOI: 10.1016/S1470-2045(15)00489-1. PMID: 26868352.

5. Rydzewska L.H.M., Burdett S., Vale C.L. et al. Adding abiraterone to androgen de¬privation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 2017;84:88-101. DOI: 10.1016/j.ejca.2017.07.003. PMID: 29573942.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes;Biomedicines;2022-01-22

2. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy;Journal of Personalized Medicine;2021-12-06

3. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1;International Journal of Molecular Sciences;2021-11-15

4. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment;International Journal of Molecular Sciences;2021-11-15

5. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models);International Journal of Molecular Sciences;2021-11-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3